Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Exact Sciences Corp. (EXAS)
NASDAQ:EXAS
Exact Sciences (EXAS) Stock Price & Analysis
3,031 Followers
EXAS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$40.62 - $100.77
Previous Close$43.19
Volume883.67K
Average Volume (3M)3.06M
Market Cap
$7.97B
Enterprise Value$9.74B
Total Cash (Recent Filing)$777.64M
Total Debt (Recent Filing)$2.55B
Price to Earnings (P/E)―
Beta1.67
Next Earnings
Jul 30, 2024EPS Estimate
-$0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.32
Shares Outstanding184,529,721
10 Day Avg. Volume3,157,930
30 Day Avg. Volume3,061,587
Standard Deviation0.16
R-Squared0.18
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)-7.44
Price to Sales (P/S)3.31
Price to Cash Flow (P/CF)29.80
P/FCF Ratio50.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.90
Enterprise Value/Gross Profit5.28
Enterprise Value/Ebitda359.53
Forecast
1Y Price Target
$77.91Price Target Upside80.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
Exact Sciences News
PremiumCompany Announcements
Exact Sciences Refines Teams, Projects Growth Amid Leadership ChangesBulls Say, Bears Say
Bulls Say
Financial PerformanceEXAS reported strong 1Q24 results with total revenues of $638 million, surpassing both internal and street estimates.
Product LaunchThere is optimism about the launch of Cologuard Plus, which is expected to further solidify EXAS as a leader in non-invasive CRC screening.
Sales And MarketingEXAS's reinvestment in their commercial engine, including aggressive hiring of sales reps and increased marketing spend, is expected to drive growth and improve sales performance.
Bears Say
Growth SkepticismInvestors may have become more skeptical about the long-term growth profile of Cologuard despite solid 1Q24 results.
Revenue ExpectationsThe 2Q revenue midpoint came in below Street expectations, leading to plans to ramp up sales and marketing spending.
Sales Force ProductivitySales force productivity related growth challenges faced by the company recently are hard to ignore.
---
Ownership Overview
3.24% Insiders
38.22% Mutual Funds
15.88% Other Institutional Investors
42.66% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EXAS FAQ
What was Exact Sciences Corp.’s price range in the past 12 months?
Exact Sciences Corp. lowest stock price was $40.62 and its highest was $100.77 in the past 12 months.
What is Exact Sciences Corp.’s market cap?
Currently, no data Available
When is Exact Sciences Corp.’s upcoming earnings report date?
Exact Sciences Corp.’s upcoming earnings report date is Jul 30, 2024 which is in 25 days.
How were Exact Sciences Corp.’s earnings last quarter?
Exact Sciences Corp. released its earnings results on May 08, 2024. The company reported -$0.6 earnings per share for the quarter, missing the consensus estimate of -$0.475 by -$0.125.
Is Exact Sciences Corp. overvalued?
According to Wall Street analysts Exact Sciences Corp.’s price is currently Undervalued.
Does Exact Sciences Corp. pay dividends?
Exact Sciences Corp. does not currently pay dividends.
What is Exact Sciences Corp.’s EPS estimate?
Exact Sciences Corp.’s EPS estimate is -$0.34.
How many shares outstanding does Exact Sciences Corp. have?
Exact Sciences Corp. has 184,529,720 shares outstanding.
What happened to Exact Sciences Corp.’s price movement after its last earnings report?
Exact Sciences Corp. reported an EPS of -$0.6 in its last earnings report, missing expectations of -$0.475. Following the earnings report the stock price went down -8.961%.
Which hedge fund is a major shareholder of Exact Sciences Corp.?
Among the largest hedge funds holding Exact Sciences Corp.’s share is ARK Investment Management LLC. It holds Exact Sciences Corp.’s shares valued at 226M.
---
Exact Sciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$77.91 (80.39% Upside)
$77.91 (80.39% Upside)
Blogger Sentiment
Bullish
EXAS Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.73%
12-Months-Change
Fundamentals
Return on Equity
-7.76%
Trailing 12-Months
Asset Growth
1.14%
Trailing 12-Months
Company Description
Exact Sciences Corp.
Founded in 1995, Wisconsin-based Exact Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer.
---
EXAS Company Deck
---
EXAS Earnings Call
Q1 2024
0:00 / 0:00
---
EXAS Revenue Breakdown
74.59% Screening
25.17% Precision Oncology
0.24% COVID-19 Testing
---
EXAS Stock 12 Month Forecast
Average Price Target
$77.91
▲(80.39% Upside)
Technical Analysis
Best Analysts Covering EXAS
1 Year
1 Year Success Rate
15/20 ratings generated profit
1 Year Average Return
+34.18%
initiated a buy rating 7 months ago
Copying Doug Schenkel's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +34.18% per trade.
---